There's still time to register for #EBMT26!🩸
Hear from Anna Sureda, the President of @theebmt.bsky.social, who shares insight into this fantastic event & invites you to join:
🎥 👉 buff.ly/oixK5Pq
Can't make it to Madrid? You can register to attend virtually instead!
Click here: ➡️ buff.ly/ahhtftc
Excitement is building for #EBMT26! 🌟🔜
From 22-25 March 2026, #Madrid 🇪🇸 will host thousands of HCP's and innovators. 🚀
Attend in-person, secure a Day Pass or join virtually and access recordings until 25 April 2026. 🎫
Register now ⬇️
https://www.ebmt.org/annual-meeting/register
EBMT 2026 is around the corner! 🔜 #EBMT26
Join thousands of HCP's in #Madrid 🇪🇸 from 22-25 March 2026. 🤩
📍 Attend in person
🎫 Get a Day Pass
💻 Or join virtually
Register here ➡️🔗 https://www.ebmt.org/annual-meeting-2026
We're thrilled to be an official media partner for #EBMT26, and we can't wait to be on-site once again, filming our expert video interviews! 🎥🩸
Interested in joining us there or attending virtually?
Click here to register now:
➡️ buff.ly/bWxuru2
#BMTsm #HemOnc #ImmunoOnc @theebmt.bsky.social
Want to find out about the latest updates and advances in transplantation and cellular therapy?🩸
Then you won't want to miss the 52nd Annual Meeting of the EBMT taking place 22–25 March in Madrid, Spain, & online.🇪🇸💻
Register here:
➡️ buff.ly/0fBo0ka
#EBMT26 #HemOnc #BMTsm @theebmt.bsky.social
Just one week to go until #CART26 kicks off in Palma de Mallorca, Spain, and online!🇪🇸 💻
Hear from the meeting chair, Annalisa Ruggeri, who encourages you to register for this hybrid meeting:
🎥 buff.ly/poXdp9x
Register here:
➡️ buff.ly/LMXQ0qU..
#CARTCell #ImmunoOnc #HemOnc @theebmt.bsky.social
Have you registered for #CART26 yet?🩸
Hear from @alexrampotas.bsky.social, who highlights the importance of the meeting as a platform for exchanging ideas & showcasing new data in the field of CAR-T & cellular therapy:
🎥 buff.ly/WhO2pQl
Register here:
👉 buff.ly/NBpWzCH
@theebmt.bsky.social
Want to find out about the latest advances in #CARTCell therapy?🩸💉
Register for the EBMT-EHA 8th European CAR T-cell Meeting taking place next month, and stay tuned for our exclusive coverage of this fantastic event!🎥
Click here to register:
👉 buff.ly/kVxJ8jg.. 👈
#CART26 @theebmt.bsky.social
We are thrilled to be the official media partner for the annual EBMT-EHA European CAR T-cell Meeting, taking place in Palma de Mallorca, Spain, from 12–14 February! 🇪🇸
Want to join us there or attend virtually?
Register here:
👉 buff.ly/HFpKa82..
#CARTCell #CART26 @theebmt.bsky.social
In an interview from #iwCLL2025, Nicolas Martinez-Calle provides insight into the UNCOVER project, which aims to evaluate inequalities in the diagnosis and survival of patients with CLL in England.
Watch here:
👉 buff.ly/FZdouqO 👈
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
🩸🎥 Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies.
Don't miss this insightful roundtable discussion from #iwAL25 with leading experts Eunice Wang, David Sallman, Gabriel Mannis, & Andrew Wei.
Watch now: 👉 buff.ly/VJJUbmz
#AMLsm #Leusm #Leukemia
At #IMS25, we spoke with Lisa Leypoldt, who shared findings from the cytogenetic subgroup analyses of the Phase II GMMG-CONCEPT trial evaluating Isa-KRd in newly diagnosed #myeloma.
Click here to watch:
🎥 buff.ly/Ut0Ne7p
#MMSM #MultipleMyeloma #CTSM #ImmunoOnc #BloodSky #HemeSky #MedSky
Thank you to Ali Taher for speaking with us recently and providing valuable insight into the management of acute complications of #thalassemia that may present to the emergency department.
Watch the interview here:
👉 buff.ly/yL0drrc 👈
#Hematology #BloodSky #HemeSky #MedSky
🎥 Vanthana Bharathi of @mdanderson.bsky.social discusses optimizing preventive care for patients with CLL using evidence-based strategies:
👉 buff.ly/BKMPQGT 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
In an interview from #SOHO2025, @krishpatelmd.bsky.social of @scri.com comments on the potential of NK cell-based therapies for B-cell lymphomas.
Click here to watch:
👉 buff.ly/jMYSlMT 👈
#LYMsm #Lymphoma #HemOnc #BloodSky #HemeSky #MedSky
🎥 Asya Varshavsky-Yanovsky shares insight into a study showing that a high peak in absolute lymphocyte count following cilta-cel infusion in patients with #myeloma predicts for increased risk of delayed neurological toxicities:
👉 buff.ly/MjL0Oku 👈
#CARTcell #MMSM #MultipleMyeloma #ImmunoOnc #IMS25
Recently, Gottfried von Keudell shared the long-term follow-up results from the Phase II ELM-2 study evaluating the efficacy of the bispecific antibody odronextamab in patients with R/R #FollicularLymphoma.
Watch here:
👉 buff.ly/6GUNfkY 👈
#ImmunoOnc #LYMsm #CTSM #TrialUpdate #SOHO2025 #MedSky
What are the key risk factors for the development of bone disease in patients with #thalassemia? 🩸🦴
Julian Waung provided insight into this in a recent interview – watch here:
👉 buff.ly/Oe2kknT 👈
#Hematology #BloodSky #HemeSky #MedSky
At #iwNHL25, Alexey Danilov of @cityofhope.bsky.social and Meghan Thompson of @mskcancercenter.bsky.social sat down to provide an update on BTK-targeting therapies in non-Hodgkin #lymphoma and CLL.🩸
This is a discussion you don't want to miss!
Click here:
🎥 buff.ly/t3TZTiT
#LYMsm #HemOnc
The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉
We recently had the pleasure of speaking to Helen Parry to find out more about the study:
🎥 buff.ly/j1K0VV8
#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc
Check out this fantastic discussion with #lymphoma experts Martin Dreyling & Georg Hess, who discuss key advances in MCL treatment. Topics covered:
🔸 The TRIANGLE trial
🔸 The role of novel agents
🔸 Treatment approaches for frontline and relapsed disease
👉 buff.ly/QbNZjR2
#LymSM #HemOnc
🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY:
👉 buff.ly/paPH5vx 👈
#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky
It was fantastic to catch up with @jmikhaelmd.bsky.social at #SOHO2025 to gain insight into areas of consensus & controversy in the current & future management of R/R #MultipleMyeloma!🩸
Watch the interview here:
👉 buff.ly/7AoA6tc 👈
#MMsm #Myeloma #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
In an interview from #iwAL25, Tara Lin discusses the possibility of tailoring treatment for secondary AML dependent on mutational profile, highlighting the heterogeneity of this disease.
Watch here:
👉 buff.ly/HbJTfmF 👈
#AMLsm #Leusm #Leukemia #HemOnc #BloodSky
It was great to catch up with the wonderful Anna Schuh at #iwCLL2025 to hear about ongoing efforts to improve the outcomes & care of patients with CLL in resource-limited settings.
Watch the interview here:
🎥 buff.ly/sZGLLe2
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
We recently had the pleasure of interviewing the lovely Payal Desai to hear about several topics in the field of #SickleCellDisease, including the potential of the six-minute walk test as a prognostic tool. 🚶
Learn more here: 👉 buff.ly/iMa7wAa
#Hematology #BloodSky #HemeSky #MedSky
Want to gain insight into the use of bispecific antibodies & other immunotherapies in early lines of treatment for #NonHodgkinLymphoma?🩸
Check out our discussion from #iwNHL25, with leading experts @DocHutchings, @elizabeth_budde, Lorenzo Falchi, & Sameh Gaballa:
🎥 buff.ly/CPiM5kC
#LYMsm #HemOnc
In a recent interview, Jesús San Miguel comments on the updated findings of the Phase III GEM2017FIT trial, which evaluated the efficacy of DaraKRd versus KRd in patients with newly diagnosed #MultipleMyeloma.
Click to watch:
👉 buff.ly/RVZjPoG 👈
#CTSM #TrialUpdate #IMS25 #MMsm #Myeloma #BloodSky
What should the optimal pre-transfusion hemoglobin target be in patients with thalassemia? 🤔🩸
We caught up with Maria Domenica Cappellini recently to find out!
Click here to watch the interview:
🎥 👉 buff.ly/B8HDjTL
#Thalassemia #Hematology #BloodSky #HemeSky #MedSky
#iwAL25 | John DiPersio comments on the challenges of treating T-cell malignancies with bispecific antibody therapy, and shares insights into the development of WU-CART-007, an anti-CD7 allogeneic CAR T-cell product:
🎥 buff.ly/s2zXiCa
#ALLsm #Leusm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
